Sponsors

At AbbVie, we have the expertise of a proven pharmaceutical leader and the focus and passion of an entrepreneur and innovator. The result is something rare in health care today – a global biopharmaceutical company that has the ability to discover and advance innovative therapies and meet the health needs of people and societies around the globe.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.

We are a global, mid-size pharmaceutical company focusing on areas of high unmet medical need.
With a focus on transformative medicines in oncology, rare disease and neuroscience, our vision is to be a leading global mid-size biopharmaceutical company. With the right combination of size and agility, we continue to push ourselves as a business and as individuals to deliver positive change.

We are a global, science-led, patient-focused pharmaceutical company.
We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.

CSL Behring is a leading global biotech company, that develops and delivers innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions live full lives.

Dr. Falk Pharma GmbH is an independent family firm based in Freiburg im Breisgau. In spite of its international presence, Dr. Falk Pharma and its 200 staff are still closely linked with the Freiburg region and the University of Freiburg. Our company specializes in the development and sales of medication for indications in hepatology and gastroenterology. These, mainly prescription drugs, are sold not only in Germany but also in a further 65 countries, often in co-operation with local partners but in some cases also via our own subsidiary companies.

At echosens, we envision a future where medical professionals and their patients have the best tools and information to assess and manage liver health.

Novo Nordisk’s purpose is to drive change to defeat serious chronic diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat.

We develop and deliver innovative therapies for patients affected by rare diseases.

With an emphasis on supporting patients, our commitment is to work collaboratively with the rare disease and scientific communities to develop evidence-based treatments in areas of unmet need. Rare disease research matters because every patient matters, irrespective of the prevalence of their illness.